Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $34.00 Consensus Price Target from Analysts

Key Points

• Karyopharm Therapeutics Inc. has received an average analyst rating of "Moderate Buy", with four analysts recommending buying the stock and one suggesting a hold.
• The company's 12-month price target is set at $34.00, though recent target adjustments have varied significantly, with some dropped to as low as $25.00.
• Karyopharm reported earnings of ($4.32) per share for the last quarter, falling short of the consensus estimate of ($3.80), despite revenue closely matching expectations.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $34.00.

A number of research analysts recently issued reports on KPTI shares. Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, August 12th. HC Wainwright downgraded Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 16th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KPTI. Jane Street Group LLC increased its holdings in Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock worth $506,000 after purchasing an additional 543,556 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in Karyopharm Therapeutics in the 1st quarter worth about $523,000. Northern Trust Corp increased its holdings in Karyopharm Therapeutics by 23.5% in the 4th quarter. Northern Trust Corp now owns 283,729 shares of the company's stock worth $192,000 after purchasing an additional 54,061 shares in the last quarter. Two Sigma Investments LP grew its position in shares of Karyopharm Therapeutics by 60.3% in the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock valued at $93,000 after buying an additional 51,856 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at about $31,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI traded down $0.02 on Monday, reaching $5.72. The company's stock had a trading volume of 15,088 shares, compared to its average volume of 122,610. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $16.95. The firm has a market cap of $49.55 million, a PE ratio of -0.39 and a beta of 0.35. The business's 50-day moving average price is $5.35 and its two-hundred day moving average price is $5.19.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The business had revenue of $37.93 million during the quarter, compared to analysts' expectations of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).